Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from ...

Analyst Jason Zemansky of Bank of America Securities reiterated a Buy rating on Keros Therapeutics (KROS – Research Report), reducing the price ...

BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

US clinical-stage pharma Keros Therapeutics today announced that it has voluntarily halted all dosing in the TROPOS trial, a ...

Keros Therapeutics, Inc. has announced a voluntary halt in dosing for the Tropos trial, a phase 2 clinical trial of ...

Hinge Bio raises $30M Series A for lupus drug; Keros halts trial dosing; Inflammasome reports eye treatment data; J&J files bladder cancer therapy; Verastem licenses KRAS drug ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

JPMorgan Chase & Co. JPM reported upbeat fourth-quarter FY24 results. Reported revenue rose 11% year-on-year to $42.8 billion. Net revenue (managed) was $43.7 billion (+10% Y/Y), beating the consensus ...

European shares were higher today. The eurozone's STOXX 600 surged 1.27%, Germany's DAX 40 gained 1.53% and France's CAC 40 gained 0.95%. Spain's IBEX 35 Index gained 1.20%, while London's FTSE 100 ...

UK clinical-stage specialty pharma firm Actimed Therapeutics has appointed Dr Fabio Dorigotti as chief medical officer (CMO) ...